Advertisement

Topics

Biosimilars are beginning to bite for Sanofi

07:08 EDT 31 Jul 2017 | BioPharmaDive

Growing competition and a tightening pricing environment has hurt Sanofi's diabetes business, but the drugmaker has two new immunology stars it hopes will take off. 

Original Article: Biosimilars are beginning to bite for Sanofi

NEXT ARTICLE

More From BioPortfolio on "Biosimilars are beginning to bite for Sanofi"

Quick Search
Advertisement
 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...